Answers are grounded in this paper and cite their sources.
Background: Two natural surfactants, Curosurf and BLES, are commonly used for the treatment of respiratory distress syndrome (RDS). Animal-derived surfactants have different pharmacological and biochemical features, and these differences might influence their clinical efficacy and complications. Objectives: The present study aimed to compare the clinical effectiveness and complications of Curosurf and BLES in the management of preterm neonates with RDS. Methods: This randomized clinical trial was conducted on 160 neonates with RDS and a gestational age of ≤ 32 weeks. Patients were randomly assigned to two intervention groups to receive either Curosurf (n = 80) or BLES (n = 80). Complications of prematurity, mortality, and the effectiveness of surfactant therapy were compared between the study groups. Results: There were statistically significant differences between the Curosurf group and the BLES group in the length of hospital stay (20.3 ± 14.4 vs. 27.3 ± 18.8 days, P = 0.01), number of surfactant injections (1.2 ± 0.4 vs. 1.4 ± 0.4, P = 0.006), and need for a second dose (21.2% vs. 41.2%, P = 0.005). In terms of complications, both groups showed no considerable differences. Conclusions: Compared to BLES, Curosurf may be more effective in the treatment of preterm neonates with RDS. Further clinical trials with robust designs and long-term follow-up are needed to compare these surfactants.
No takes yet. Share an insight, caveat, or question.
Ostadmohammadi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: